Abbott India Limited reported earnings results for the third quarter and nine months ended December 31, 2025. For the third quarter, the company reported sales was INR 17,240.4 million compared to INR 16,142.8 million a year ago. Revenue was INR 17,938 million compared to INR 16,860.3 million a year ago. Net income was INR 3,759.6 million compared to INR 3,607.8 million a year ago. Basic earnings per share from continuing operations was INR 176.92 compared to INR 169.78 a year ago. Diluted earnings per share from continuing operations was INR 176.92 compared to INR 169.78 a year ago.
For the nine months, sales was INR 52,195.4 million compared to INR 48,045.6 million a year ago. Revenue was INR 54,320.9 million compared to INR 50,041.2 million a year ago. Net income was INR 11,570.9 million compared to INR 10,474 million a year ago. Basic earnings per share from continuing operations was INR 544.51 compared to INR 492.89 a year ago. Diluted earnings per share from continuing operations was INR 544.51 compared to INR 492.89 a year ago.
Abbott India Limited is an India-based company engaged in the pharmaceuticals business. The Company is involved in product development, manufacturing, and sales of healthcare products. It operates in a single reportable business segment, which is Pharmaceuticals. It distributes products and solutions in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders, Central Nervous System, Vaccines, Multi-Specialty, and primary care. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Cremaffin Plus (Constipation), Pankreoflat (indigestion), Brufen P (fever), and Duvadilan (preterm labor). It offers various products under brands such as Similac, PediaSure, Pedialyte, EleCare, Ensure, and Glucerna.
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
-
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
